Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda was able to reduce the time patients spent in the chemotherapy chair.

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year.

China National Medical Products Administration (NMPA) has approved MSD’s KEYTRUDA for use in conjunction with platinum-containing chemotherapy as a neoadjuvant treatment and as a single agent ...

Merck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell lung cancer (NSCLC) as part of a regimen with chemotherapy, says NICE. Draft ...

MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK) announced today that KEYTRUDA is now registered to treat patients with the following cancers: Malignant Pleural Mesothelioma (MPM ...

MSD’s subcutaneous (SC) Keytruda (pembrolizumab) has shown non-inferior pharmacokinetics (PK) to the intravenous (IV) version of the company’s blockbuster therapy in a pivotal trial.